


Interleukin-17A-Inhibition mit Secukinumab: 8 Indikationen in 8 Jahren

Mehr als 1 Million Patient*innen weltweit mit Secukinumab behandelt¹



Abkürzungsverzeichnis:
AS = ankylosierende Spondylitis
EAA = Entesitis assoziierte Arthritis
HS = Hidradenitis suppurativa
JPsA = Juvenile Psoriasis-Arthritis
nr-axSpA = nicht-röntgenologische axiale Spondyloarthritis
päd. PsO = pädiatrische Plaque Psoriasis
PsA = Psoriasis-Arthritis
PsO = Derma-Indikationen Plaque-Psoriasis

Referenzen:
1. Novartis. Accessed: 7. June 2023. https://www.novartis.com/sites/novartis_com/files/2023-04-interim-financial-report-en.pdf
2. Rouvier E et al. J Immunol Baltim Md 1950. 1993;150(12):5445-5456.
3. Novartis AG, Basel (CH). :US Patent No. 7,807,155 B2. United States Patent.
4. Novartis Pharmaceuticals. Phase 2a Single-Dose, Randomized, Double Blind, Multi-Center, Parallel-Group, Placebo-Controlled Proof of Concept Study to Assess the Efficacy, Safety, Tolerability, and Population Pharmacokinetics of AIN457 in Patients With Stable Plaque-Type Psoriasis. clinicaltrials.gov; 2015. Accessed: 19. April 2023. <https://clinicaltrials.gov/ct2/show/study/NCT00669916>
5. Fachinformation Cosentyx®.